198 related articles for article (PubMed ID: 27498589)
1. Comprehensive evaluation of liver microsomal cytochrome P450 3A (CYP3A) inhibition: comparison of cynomolgus monkey and human.
Haarhoff ZE; Kramer MA; Zvyaga TA; Zhang J; Bhutani P; Subramanian M; Rodrigues AD
Xenobiotica; 2017 Jun; 47(6):470-478. PubMed ID: 27498589
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma.
Mao J; Tay S; Khojasteh CS; Chen Y; Hop CE; Kenny JR
Pharm Res; 2016 May; 33(5):1204-19. PubMed ID: 26869174
[TBL] [Abstract][Full Text] [Related]
3. Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes.
Tseng E; Eng H; Lin J; Cerny MA; Tess DA; Goosen TC; Obach RS
Drug Metab Dispos; 2021 Oct; 49(10):947-960. PubMed ID: 34326140
[TBL] [Abstract][Full Text] [Related]
4. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans.
Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
Xenobiotica; 2004 May; 34(5):391-402. PubMed ID: 15370956
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous evaluation of substrate-dependent CYP3A inhibition using a CYP3A probe substrates cocktail.
Lee E; Shon JC; Liu KH
Biopharm Drug Dispos; 2016 Sep; 37(6):366-72. PubMed ID: 27323294
[TBL] [Abstract][Full Text] [Related]
6. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
Watanabe A; Nakamura K; Okudaira N; Okazaki O; Sudo K
Drug Metab Dispos; 2007 Jul; 35(7):1232-8. PubMed ID: 17392390
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
Guo J; Zhou D; Li Y; Khanh BH
Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
[TBL] [Abstract][Full Text] [Related]
8. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.
Xu L; Chen Y; Pan Y; Skiles GL; Shou M
Drug Metab Dispos; 2009 Dec; 37(12):2330-9. PubMed ID: 19773538
[TBL] [Abstract][Full Text] [Related]
9. Reversible, time-dependent inhibition of CYP3A-mediated metabolism of midazolam and tacrolimus by telaprevir in human liver microsomes.
Chapron B; Risler L; Phillips B; Collins C; Thummel K; Shen D
J Pharm Pharm Sci; 2015; 18(1):101-11. PubMed ID: 25877445
[TBL] [Abstract][Full Text] [Related]
10. Expression and characterization of cynomolgus monkey cytochrome CYP3A4 in a novel human embryonic kidney cell-based mammalian system.
Selvakumar S; Bhutani P; Ghosh K; Krishnamurthy P; Kallipatti S; Selvam S; Ramarao M; Mandlekar S; Sinz MW; Rodrigues AD; Subramanian M
Drug Metab Dispos; 2014 Mar; 42(3):369-76. PubMed ID: 24335510
[TBL] [Abstract][Full Text] [Related]
11. VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.
Zetterberg C; Maltais F; Laitinen L; Liao S; Tsao H; Chakilam A; Hariparsad N
Drug Metab Dispos; 2016 Aug; 44(8):1286-95. PubMed ID: 27298338
[TBL] [Abstract][Full Text] [Related]
12. Marmoset Cytochrome P450 3A4 Ortholog Expressed in Liver and Small-Intestine Tissues Efficiently Metabolizes Midazolam, Alprazolam, Nifedipine, and Testosterone.
Uehara S; Uno Y; Nakanishi K; Ishii S; Inoue T; Sasaki E; Yamazaki H
Drug Metab Dispos; 2017 May; 45(5):457-467. PubMed ID: 28196829
[TBL] [Abstract][Full Text] [Related]
13. Oxidation of R- and S-omeprazole stereoselectively mediated by liver microsomal cytochrome P450 2C19 enzymes from cynomolgus monkeys and common marmosets.
Uehara S; Kawano M; Murayama N; Uno Y; Utoh M; Inoue T; Sasaki E; Yamazaki H
Biochem Pharmacol; 2016 Nov; 120():56-62. PubMed ID: 27641812
[TBL] [Abstract][Full Text] [Related]
14. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
Polasek TM; Miners JO
Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
[TBL] [Abstract][Full Text] [Related]
15. Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes - detailed studies on CYP3A inhibitors.
Kahma H; Paludetto MN; Neuvonen M; Kurkela M; Filppula AM; Niemi M; Backman JT
Eur J Pharm Sci; 2024 Jul; 198():106735. PubMed ID: 38423227
[TBL] [Abstract][Full Text] [Related]
16. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
Mao J; Johnson TR; Shen Z; Yamazaki S
Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
[TBL] [Abstract][Full Text] [Related]
17. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
Yu Y; Loi CM; Hoffman J; Wang D
J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
[TBL] [Abstract][Full Text] [Related]
18. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
Ma B; Prueksaritanont T; Lin JH
Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508
[TBL] [Abstract][Full Text] [Related]
19. Risk Assessment Using Cytochrome P450 Time-Dependent Inhibition Assays at Single Time and Concentration in the Early Stage of Drug Discovery.
Kosaka M; Kosugi Y; Hirabayashi H
J Pharm Sci; 2017 Sep; 106(9):2839-2846. PubMed ID: 28483425
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate Constants.
Eng H; Tseng E; Cerny MA; Goosen TC; Obach RS
Drug Metab Dispos; 2020 Jun; 49(6):442-450. PubMed ID: 33811106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]